Alicia Novak
Family · Olyphant, PANPI 1902314180
Payments from drug & device makers
Across 817 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Dexcom, Inc.$960
- Amgen$808
- Sanofi-aventis U.S. LLC$786
- AstraZeneca$714
- plus $5K from 32 others
What the payments were for
- Food & beverage$11,570100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 164 | $1,805 |
| Lilly USA, LLC | 97 | $1,230 |
| Dexcom, Inc. | 69 | $960 |
| Amgen | 57 | $808 |
| Sanofi-aventis U.S. LLC | 79 | $786 |
| AstraZeneca(2 entities) | 36 | $714 |
| Boehringer Ingelheim | 52 | $707 |
| Abbott | 44 | $637 |
| AbbVie | 40 | $618 |
| Medtronic | 14 | $507 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $307 |
| Xeris Pharmaceuticals, Inc. | 18 | $290 |
| Antares Pharma, Inc. | 21 | $270 |
| Amarin Pharma, Inc. | 20 | $261 |
| Merck | 15 | $235 |
| Tandem Diabetes Care, Inc. | 11 | $156 |
| Boston Scientific | 1 | $137 |
| Cequr Corporation | 3 | $127 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Novartis | 7 | $111 |
| Bayer | 6 | $92 |
| Tolmar, Inc. | 5 | $90 |
| Regeneron Healthcare Solutions, Inc. | 5 | $78 |
| Zealand Pharma US, Inc. | 5 | $74 |
| Nestle Healthcare Nutrition Inc. | 4 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Radius Health, Inc. | 3 | $48 |
| Halozyme Inc | 3 | $46 |
| IBSA Pharma Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $41 |
| Johnson & Johnson | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| QOL Medical, LLC | 1 | $15 |
| Insulet Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,582 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 543 | $682,224 |
| MounjaroTirzepatide | 373 | $452,609 |
| JardianceEmpagliflozin | 384 | $314,981 |
| TrulicityDulaglutide | 169 | $179,411 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 173 | $159,215 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 115 | $156,513 |
| JanuviaSitagliptin Phosphate | 130 | $102,500 |
| TradjentaLinagliptin | 136 | $98,854 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 88 | $91,886 |
| FarxigaDapagliflozin Propanediol | 98 | $88,891 |
| Tresiba Flextouch U-100Insulin Degludec | 104 | $82,606 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $71,513 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 77 | $62,570 |
| Novolog FlexpenInsulin Aspart | 197 | $48,129 |
| GlyxambiEmpagliflozin/Linagliptin | 46 | $41,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,805 | $701,434586 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $1,230 | $639,794559 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi | $707 | $614,888739 claims |
| MerckJanuvia, Janumet Xr, Janumet | $235 | $130,730164 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $786 | $91,88688 claims |
| AstraZenecaFarxiga | $714 | $88,89198 claims |
| Johnson & JohnsonInvokana | $29 | $33,47329 claims |
| AbbVieSynthroid | $618 | $20,172309 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $9,9821,031 claims |
| Antares Pharma, Inc.Xyosted | $270 | $7,74013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Olyphant
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.